It will take more than a little heat and humidity to stop our researchers at Children’s Hospital of Philadelphia from making an impact in and around the community: In this edition of our biweekly news roundup, we cover a recent event that introduced South Jersey teachers to our innovative research, congratulate two scientists on new awards that recognize their contributions to rheumatology and hematology, and share how faculty members at PolicyLab are discussing the implications of their work in the realms of policy and public health.
Tag Archive: Sriram Krishnaswamy
Thrombosis — the abnormal, life-threatening blood clots that form in the artery or vein — does not discriminate. Young. Old. Rich. Poor. Gender. Race. Ethnicity. We’re all in this together. We’re all susceptible. Some more so than others.
Up to 900,000 people in the U.S. are affected by blood clots each year; 100,000 will die, which is greater than the total number of people who lose their lives each year to AIDS, breast cancer, and motor vehicle crashes combined.
Hematologists have grappled for many years to understand the basic mechanisms underlying why some young patients with the inherited bleeding disorder hemophilia A develop inhibitory antibodies, also known as factor VIII (FVIII) inhibitors, to protein replacement therapy. The presence of FVIII inhibitors is a serious obstacle that makes it difficult and extremely expensive to treat their hemophilia, leads to complications such as joint disease, and increases mortality.
Such a major challenge requires major brain power. So the National Institutes of Health called on the scientific community to reframe the question: Why is FVIII so immunogenic?
From the discovery of stem cells that multiply after a lung injury, to new data that advances how we think about (and treat) childhood cancer, our first roundup of March is packed with discovery. Read on to learn how our researchers stay at the forefront of pediatric science with a new study that expands what scientists know about the body’s extraordinary ability to regenerate, a pan-cancer project that distinguishes how cancer develops in children versus adults, and a handful of updates on what our investigators have in store for the near future.